| Assay ID | Title | Year | Journal | Article |
|---|
| AID1729513 | Antiproliferative activity against human MIA PaCa-2 cells harboring KRAS G12C mutant assessed as growth inhibition at 0.1 uM measured after 72 hrs by CCK8 assay relative to control | 2021 | European journal of medicinal chemistry, Mar-05, Volume: 213 | Design, synthesis and pharmacological evaluation of bicyclic and tetracyclic pyridopyrimidinone analogues as new KRAS |
| AID1716430 | Antiproliferative activity against human NCI-H358 cells harboring KRAS G12C mutant assessed as reduction in cell viability | 2018 | ACS medicinal chemistry letters, Jun-14, Volume: 9, Issue:6
| Chemical Proteomic Characterization of a Covalent KRASG12C Inhibitor. |
| AID1716411 | Covalent binding affinity to KRAS G12C mutant at Cys12 residue in human NCI-H358 cells assessed as reduction of log2 H/L ratio for tryptic peptide LVVVGACGVGK at 2 uM incubated for 4 hrs followed by cell lysis and subsequently labelled with light thiol pr | 2018 | ACS medicinal chemistry letters, Jun-14, Volume: 9, Issue:6
| Chemical Proteomic Characterization of a Covalent KRASG12C Inhibitor. |
| AID1856088 | Toxicity in nude mouse xenografted with human NCI-H358 cells assessed as morphological abnormalities in liver by hematoxylin and eosin staining based microscopic analysis | 2022 | Bioorganic & medicinal chemistry, 10-01, Volume: 71 | Discovery of novel Quinazoline-based KRAS G12C inhibitors as potential anticancer agents. |
| AID1904843 | Antiproliferative activity against human NCI-H358 cells harboring KRAS G12C mutant assessed as inhibition of cell viability after 24 hrs by MTT assay | 2022 | European journal of medicinal chemistry, Apr-05, Volume: 233 | Discovery of Thieno[2,3-d]pyrimidine-based KRAS G12D inhibitors as potential anticancer agents via combinatorial virtual screening. |
| AID1768830 | Binding affinity to KRAS G12C mutant (unknown origin) by traditional Western blot CETSA analysis | 2021 | ACS medicinal chemistry letters, Aug-12, Volume: 12, Issue:8
| Rapid Evaluation of Small Molecule Cellular Target Engagement with a Luminescent Thermal Shift Assay. |
| AID1904842 | Antiproliferative activity against human HCT-116 cells harboring KRAS G13D mutant assessed as inhibition of cell viability after 24 hrs by MTT assay | 2022 | European journal of medicinal chemistry, Apr-05, Volume: 233 | Discovery of Thieno[2,3-d]pyrimidine-based KRAS G12D inhibitors as potential anticancer agents via combinatorial virtual screening. |
| AID1716419 | Covalent binding affinity to FAM213A in human NCI-H358 cells assessed as log2 H/L ratio at 10 uM pretreated for 3 hrs followed by N-(((6S,7R)-7-(4-chloro-3-fluorophenyl)-1,4-oxazepan-6-yl)methyl)-2-hydroxyacetamide treatment for 3 hrs by competitive TMT c | 2018 | ACS medicinal chemistry letters, Jun-14, Volume: 9, Issue:6
| Chemical Proteomic Characterization of a Covalent KRASG12C Inhibitor. |
| AID1893947 | Inhibition of recombinant full length FLAG tagged KRAS G12C mutant (1 to 169 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) | 2021 | European journal of medicinal chemistry, Feb-05, Volume: 211 | Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway. |
| AID1856038 | Antiproliferative activity against human NCI-H358 cells harboring KRAS G12C mutant assessed as inhibition of cell growth incubated for 24 hrs by MTT assay | 2022 | Bioorganic & medicinal chemistry, 10-01, Volume: 71 | Discovery of novel Quinazoline-based KRAS G12C inhibitors as potential anticancer agents. |
| AID1716417 | Covalent binding affinity to FABP5 at Cys67 residue in human NCI-H358 cells assessed as log2 H/L ratio at 10 uM pretreated for 3 hrs followed by N-(((6S,7R)-7-(4-chloro-3-fluorophenyl)-1,4-oxazepan-6-yl)methyl)-2-hydroxyacetamide treatment for 3 hrs by co | 2018 | ACS medicinal chemistry letters, Jun-14, Volume: 9, Issue:6
| Chemical Proteomic Characterization of a Covalent KRASG12C Inhibitor. |
| AID1729518 | Antiproliferative activity against human A549 cells harboring KRAS G12S mutant assessed as growth inhibition at 10 uM measured after 72 hrs by SRB assay relative to control | 2021 | European journal of medicinal chemistry, Mar-05, Volume: 213 | Design, synthesis and pharmacological evaluation of bicyclic and tetracyclic pyridopyrimidinone analogues as new KRAS |
| AID1716423 | Covalent binding affinity to HMOX2 at Cys282 residue in human NCI-H358 cells assessed as reduction of log2 H/L ratio for tryptic peptide GALEGSSCPFR incubated for 4 hrs followed by cell lysis and subsequently labelled with light thiol probe N-((S)-18-iodo | 2018 | ACS medicinal chemistry letters, Jun-14, Volume: 9, Issue:6
| Chemical Proteomic Characterization of a Covalent KRASG12C Inhibitor. |
| AID1889607 | Binding affinity to KRAS (unknown origin) assessed as inactivation constant | 2022 | Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
| Drugging the Next Undruggable KRAS Allele-Gly12Asp. |
| AID1904841 | Antiproliferative activity against human SW1990 cells harboring KRAS G12D mutant assessed as inhibition of cell viability after 24 hrs by MTT assay | 2022 | European journal of medicinal chemistry, Apr-05, Volume: 233 | Discovery of Thieno[2,3-d]pyrimidine-based KRAS G12D inhibitors as potential anticancer agents via combinatorial virtual screening. |
| AID1716435 | Covalent binding affinity to VAT1 at Cys residue in human NCI-H358 cells assessed as reduction of log2 H/L ratio for tryptic peptide CLVLTGFGGYDK incubated for 4 hrs followed by cell lysis and subsequently labelled with light thiol probe N-((S)-18-iodo-11 | 2018 | ACS medicinal chemistry letters, Jun-14, Volume: 9, Issue:6
| Chemical Proteomic Characterization of a Covalent KRASG12C Inhibitor. |
| AID1716425 | Covalent binding affinity to KRAS G12C mutant at Cys12 residue in human NCI-H358 cells assessed as reduction of log2 H/L ratio for tryptic peptide LVVVGACGVGK incubated for 4 hrs followed by cell lysis and subsequently labelled with light thiol probe N-(( | 2018 | ACS medicinal chemistry letters, Jun-14, Volume: 9, Issue:6
| Chemical Proteomic Characterization of a Covalent KRASG12C Inhibitor. |
| AID1683234 | Binding affinity to human hexahistidine-tagged KRas G12C mutant (1 to 169 residues) expressed in Escherichia coli(BL21 (DE3)) assessed as rate constant for covalent modification by measuring Kobs/[I] at 10 uM by liquid chromatography-electrospray mass spe | 2020 | Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
| Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics. |
| AID1387523 | Ratio of Kinact to Ki for hexahistidine-tagged recombinant human KRas G12C mutant expressed in Escherichia coli BL21 (DE3) | 2018 | ACS medicinal chemistry letters, Sep-13, Volume: 9, Issue:9
| Precedence and Promise of Covalent Inhibitors of EGFR and KRAS for Patients with Non-Small-Cell Lung Cancer. |
| AID1514553 | Ratio of Kinact to Ki for GDP-loaded His6-tagged KRAS G12C mutant (unknown origin) expressed in RAS-deficient MEF assessed as reduction in SOS-mediated mant-GDP-GTP exchange | 2019 | Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1
| Discovery of covalent enzyme inhibitors using virtual docking of covalent fragments. |
| AID1716414 | Covalent binding affinity to RTN4 at Cys1101 residue in human NCI-H358 cells assessed as log2 H/L ratio at 10 uM pretreated for 3 hrs followed by N-(((6S,7R)-7-(4-chloro-3-fluorophenyl)-1,4-oxazepan-6-yl)methyl)-2-hydroxyacetamide treatment for 3 hrs by c | 2018 | ACS medicinal chemistry letters, Jun-14, Volume: 9, Issue:6
| Chemical Proteomic Characterization of a Covalent KRASG12C Inhibitor. |
| AID1729516 | Antiproliferative activity against human A549 cells harboring KRAS G12S mutant assessed as growth inhibition at 0.1 uM measured after 72 hrs by SRB assay relative to control | 2021 | European journal of medicinal chemistry, Mar-05, Volume: 213 | Design, synthesis and pharmacological evaluation of bicyclic and tetracyclic pyridopyrimidinone analogues as new KRAS |
| AID1856086 | Toxicity in nude mouse xenografted with human NCI-H358 cells assessed as morphological abnormalities in kidney by hematoxylin and eosin staining based microscopic analysis | 2022 | Bioorganic & medicinal chemistry, 10-01, Volume: 71 | Discovery of novel Quinazoline-based KRAS G12C inhibitors as potential anticancer agents. |
| AID1716429 | Antiproliferative activity against human NCI-H23 cells harboring KRAS G12C mutant assessed as reduction in cell viability | 2018 | ACS medicinal chemistry letters, Jun-14, Volume: 9, Issue:6
| Chemical Proteomic Characterization of a Covalent KRASG12C Inhibitor. |
| AID1904834 | Antiproliferative activity against human PANC1 cells harboring KRAS G12D mutant assessed as inhibition of cell viability after 24 hrs by MTT assay | 2022 | European journal of medicinal chemistry, Apr-05, Volume: 233 | Discovery of Thieno[2,3-d]pyrimidine-based KRAS G12D inhibitors as potential anticancer agents via combinatorial virtual screening. |
| AID1729514 | Antiproliferative activity against human MIA PaCa-2 cells harboring KRAS G12C mutant assessed as growth inhibition at 1 uM measured after 72 hrs by CCK8 assay relative to control | 2021 | European journal of medicinal chemistry, Mar-05, Volume: 213 | Design, synthesis and pharmacological evaluation of bicyclic and tetracyclic pyridopyrimidinone analogues as new KRAS |
| AID1716427 | Antiproliferative activity against human MIA PaCa-2 cells harboring KRAS G12C mutant assessed as reduction in cell viability | 2018 | ACS medicinal chemistry letters, Jun-14, Volume: 9, Issue:6
| Chemical Proteomic Characterization of a Covalent KRASG12C Inhibitor. |
| AID1652156 | Inhibition of recombinant KRAS G12C mutant (unknown origin) assessed as Kinact/Ki ratio by LC-MS analysis | 2020 | Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13
| Identification of the Clinical Development Candidate |
| AID1716426 | Covalent binding affinity to KRAS G12C mutant at Cys12 residue in human NCI-H358 cells assessed as reduction of log2 H/L ratio for tryptic peptide LVVVGACGVGK incubated for 4 hrs followed by cell lysis and subsequently labelled with light thiol probe N-(( | 2018 | ACS medicinal chemistry letters, Jun-14, Volume: 9, Issue:6
| Chemical Proteomic Characterization of a Covalent KRASG12C Inhibitor. |
| AID1716431 | Covalent inhibition of GDP bound His-tagged KRAS G12C/C51L/C80L/C118S mutant (1 to 169 residues) (unknown origin) expressed in Escherichia coli assessed as enzyme-compound adduct formation at Cys12 residue by measuring ratio of Kinact/Ki measured up to 20 | 2018 | ACS medicinal chemistry letters, Jun-14, Volume: 9, Issue:6
| Chemical Proteomic Characterization of a Covalent KRASG12C Inhibitor. |
| AID1559566 | Inhibition of GDP bound recombinant human His-tagged KRAS G12C/C118A mutant (1 to 169 residues) assessed as reduction in SOS1-mediated GDP/GTP nucleotide exchange by measuring the disruption between GDP-bound recombinant His-tagged KRAS G12C/C118A (1 to 1 | | | |
| AID1716432 | Covalent inhibition of GDP bound His-tagged KRAS G12C/C51L/C80L/C118S mutant (1 to 169 residues) (unknown origin) expressed in Escherichia coli assessed as enzyme-compound adduct formation at Cys12 residue by measuring ratio of Kinact/Ki measured up to 20 | 2018 | ACS medicinal chemistry letters, Jun-14, Volume: 9, Issue:6
| Chemical Proteomic Characterization of a Covalent KRASG12C Inhibitor. |
| AID1716415 | Covalent binding affinity to VAT1 at Cys86 residue in human NCI-H358 cells assessed as log2 H/L ratio at 10 uM pretreated for 3 hrs followed by N-(((6S,7R)-7-(4-chloro-3-fluorophenyl)-1,4-oxazepan-6-yl)methyl)-2-hydroxyacetamide treatment for 3 hrs by com | 2018 | ACS medicinal chemistry letters, Jun-14, Volume: 9, Issue:6
| Chemical Proteomic Characterization of a Covalent KRASG12C Inhibitor. |
| AID1716421 | Covalent binding affinity to RTN4 at Cys1101 residue in human NCI-H358 cells assessed as reduction of log2 H/L ratio for tryptic peptide YSNSALGHVNCTIK incubated for 4 hrs followed by cell lysis and subsequently labelled with light thiol probe N-((S)-18-i | 2018 | ACS medicinal chemistry letters, Jun-14, Volume: 9, Issue:6
| Chemical Proteomic Characterization of a Covalent KRASG12C Inhibitor. |
| AID1387522 | Binding affinity to hexahistidine-tagged recombinant human KRas G12C mutant expressed in Escherichia coli BL21 (DE3) assessed as first-order rate constant in presence of GDP | 2018 | ACS medicinal chemistry letters, Sep-13, Volume: 9, Issue:9
| Precedence and Promise of Covalent Inhibitors of EGFR and KRAS for Patients with Non-Small-Cell Lung Cancer. |
| AID1387521 | Binding affinity to hexahistidine-tagged recombinant human KRas G12C mutant expressed in Escherichia coli BL21 (DE3) in presence of GDP | 2018 | ACS medicinal chemistry letters, Sep-13, Volume: 9, Issue:9
| Precedence and Promise of Covalent Inhibitors of EGFR and KRAS for Patients with Non-Small-Cell Lung Cancer. |
| AID1559567 | Inhibition of KRAS in human MIAPaca2 cells assessed as decrease in EGF-stimulated ERK1/2 phosphorylation preincubated for 2 hrs followed by EGF stimulation | | | |
| AID1716424 | Covalent binding affinity to VAT1 at Cys residue in human NCI-H358 cells assessed as reduction of log2 H/L ratio for tryptic peptide ACGLNFADLMAR incubated for 4 hrs followed by cell lysis and subsequently labelled with light thiol probe N-((S)-18-iodo-11 | 2018 | ACS medicinal chemistry letters, Jun-14, Volume: 9, Issue:6
| Chemical Proteomic Characterization of a Covalent KRASG12C Inhibitor. |
| AID1904845 | Antiproliferative activity against mouse CT26 cells harboring KRAS G12D mutant assessed as inhibition of cell viability after 24 hrs by MTT assay | 2022 | European journal of medicinal chemistry, Apr-05, Volume: 233 | Discovery of Thieno[2,3-d]pyrimidine-based KRAS G12D inhibitors as potential anticancer agents via combinatorial virtual screening. |
| AID1856080 | Antitumor activity against human NCI-H358 cells xenografted in nude mouse assessed as tumor growth inhibition | 2022 | Bioorganic & medicinal chemistry, 10-01, Volume: 71 | Discovery of novel Quinazoline-based KRAS G12C inhibitors as potential anticancer agents. |
| AID1729517 | Antiproliferative activity against human A549 cells harboring KRAS G12S mutant assessed as growth inhibition at 1 uM measured after 72 hrs by SRB assay relative to control | 2021 | European journal of medicinal chemistry, Mar-05, Volume: 213 | Design, synthesis and pharmacological evaluation of bicyclic and tetracyclic pyridopyrimidinone analogues as new KRAS |
| AID1889606 | Binding affinity to KRAS (unknown origin) assessed as inhibition constant | 2022 | Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
| Drugging the Next Undruggable KRAS Allele-Gly12Asp. |
| AID1716416 | Covalent binding affinity to ALDH1A3 at Cys52 residue in human NCI-H358 cells assessed as log2 H/L ratio at 10 uM pretreated for 3 hrs followed by N-(((6S,7R)-7-(4-chloro-3-fluorophenyl)-1,4-oxazepan-6-yl)methyl)-2-hydroxyacetamide treatment for 3 hrs by | 2018 | ACS medicinal chemistry letters, Jun-14, Volume: 9, Issue:6
| Chemical Proteomic Characterization of a Covalent KRASG12C Inhibitor. |
| AID1856087 | Toxicity in nude mouse xenografted with human NCI-H358 cells assessed as morphological abnormalities in heart by hematoxylin and eosin staining based microscopic analysis | 2022 | Bioorganic & medicinal chemistry, 10-01, Volume: 71 | Discovery of novel Quinazoline-based KRAS G12C inhibitors as potential anticancer agents. |
| AID1683233 | Inhibition of KRas G12C mutant in human H358 cells assessed as reduction in ERK phosphorylation at T202/Y204 residue incubated for 24 hrs by immunoblot analysis | 2020 | Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
| Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics. |
| AID1716422 | Covalent binding affinity to CRYZ at Cys45 residue in human NCI-H358 cells assessed as reduction of log2 H/L ratio for tryptic peptide VHACGVNPVETYIR incubated for 4 hrs followed by cell lysis and subsequently labelled with light thiol probe N-((S)-18-iod | 2018 | ACS medicinal chemistry letters, Jun-14, Volume: 9, Issue:6
| Chemical Proteomic Characterization of a Covalent KRASG12C Inhibitor. |
| AID1716418 | Covalent binding affinity to KRAS G12C mutant at Cys12 residue in human NCI-H358 cells assessed as log2 H/L ratio at 10 uM pretreated for 3 hrs followed by N-(((6S,7R)-7-(4-chloro-3-fluorophenyl)-1,4-oxazepan-6-yl)methyl)-2-hydroxyacetamide treatment for | 2018 | ACS medicinal chemistry letters, Jun-14, Volume: 9, Issue:6
| Chemical Proteomic Characterization of a Covalent KRASG12C Inhibitor. |
| AID1768833 | Binding affinity to HiBiT-tagged KRAS G12C mutant in human NCI-H358 cells assessed as stabilization by measuring luminescence signal by BiTSA-ITDR assay | 2021 | ACS medicinal chemistry letters, Aug-12, Volume: 12, Issue:8
| Rapid Evaluation of Small Molecule Cellular Target Engagement with a Luminescent Thermal Shift Assay. |
| AID1716412 | Covalent binding affinity to CRYZ at Cys45 residue in human NCI-H358 cells assessed as log2 H/L ratio at 10 uM pretreated for 3 hrs followed by N-(((6S,7R)-7-(4-chloro-3-fluorophenyl)-1,4-oxazepan-6-yl)methyl)-2-hydroxyacetamide treatment for 3 hrs by com | 2018 | ACS medicinal chemistry letters, Jun-14, Volume: 9, Issue:6
| Chemical Proteomic Characterization of a Covalent KRASG12C Inhibitor. |
| AID1716420 | Covalent binding affinity to FAM213A in human NCI-H358 cells incubated for 4 hrs followed by cell lysis and subsequently labelled with light thiol probe N-((S)-18-iodo-11-isopropyl-10,13,17-trioxo-3,6-dioxa-9,12,16-triazaoctadecyl)-6-((4R,5S)-5-methyl-2-o | 2018 | ACS medicinal chemistry letters, Jun-14, Volume: 9, Issue:6
| Chemical Proteomic Characterization of a Covalent KRASG12C Inhibitor. |
| AID1856039 | Antiproliferative activity against human NCI-H23 cells harboring KRAS G12C mutant assessed as inhibition of cell growth incubated for 24 hrs by MTT assay | 2022 | Bioorganic & medicinal chemistry, 10-01, Volume: 71 | Discovery of novel Quinazoline-based KRAS G12C inhibitors as potential anticancer agents. |
| AID1716413 | Covalent binding affinity to HMOX2 at Cys282 residue in human NCI-H358 cells assessed as log2 H/L ratio at 10 uM pretreated for 3 hrs followed by N-(((6S,7R)-7-(4-chloro-3-fluorophenyl)-1,4-oxazepan-6-yl)methyl)-2-hydroxyacetamide treatment for 3 hrs by c | 2018 | ACS medicinal chemistry letters, Jun-14, Volume: 9, Issue:6
| Chemical Proteomic Characterization of a Covalent KRASG12C Inhibitor. |
| AID1729519 | Antiproliferative activity against human MIA PaCa-2 cells harboring KRAS G12C mutant assessed as growth inhibition measured after 72 hrs by CCK8 assay | 2021 | European journal of medicinal chemistry, Mar-05, Volume: 213 | Design, synthesis and pharmacological evaluation of bicyclic and tetracyclic pyridopyrimidinone analogues as new KRAS |
| AID1716428 | Antiproliferative activity against human NCI-H2030 cells harboring KRAS G12C mutant assessed as reduction in cell viability | 2018 | ACS medicinal chemistry letters, Jun-14, Volume: 9, Issue:6
| Chemical Proteomic Characterization of a Covalent KRASG12C Inhibitor. |
| AID1729515 | Antiproliferative activity against human MIA PaCa-2 cells harboring KRAS G12C mutant assessed as growth inhibition at 10 uM measured after 72 hrs by CCK8 assay relative to control | 2021 | European journal of medicinal chemistry, Mar-05, Volume: 213 | Design, synthesis and pharmacological evaluation of bicyclic and tetracyclic pyridopyrimidinone analogues as new KRAS |
| AID1904844 | Antiproliferative activity against human HeLa cells harboring wild type KRAS assessed as inhibition of cell viability after 24 hrs by MTT assay | 2022 | European journal of medicinal chemistry, Apr-05, Volume: 233 | Discovery of Thieno[2,3-d]pyrimidine-based KRAS G12D inhibitors as potential anticancer agents via combinatorial virtual screening. |
| AID1889608 | Binding affinity to KRAS (unknown origin) assessed as ratio of inactivation constant to inhibition constant | 2022 | Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
| Drugging the Next Undruggable KRAS Allele-Gly12Asp. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |